Answers are grounded in this paper and cite their sources.
Reviews emerging weight loss interventions and procedural innovations, highlighting the need for rigorous placebo-controlled trials.
Obesity is in the top three social burdens faced by humankind1. It leads to multiple health problems, impacting on quality of life, and reducing people’s ability to work; it also increases the incidence of some cancers and reduces life expectancy. On a national level, it results in increased healthcare utilization and costs. Few areas of surgery have not been affected by the rise in obesity in the last two decades. While there may be a tendency to regard obesity as a self-inflicted lifestyle choice, the classification of obesity as a disease with a genetic basis and a metabolic disturbance was recognized by the World Health Organization (WHO) in 1997 and the National Institute for Health and Care Excellence in 2007. Bariatric surgery is an effective intervention for obesity, achieving long-term significant weight loss, and is safe2,3. Although surgery is relatively expensive initially, it is cost-saving compared to medical management over a 5-year period, resulting in a saving of UK £4200 per patient4. However, at present, most eligible patients are not offered surgical intervention. This is a result of the large and increasing numbers of patients with obesity, and considerable disparities in the provision of bariatric services. Obesity is defined as BMI > 30 kg/m2. Any treatment that causes 5 per cent weight loss or more is highly clinically relevant and of importance. Weight loss of 5 to 10 per cent reduces cardiovascular risk factors and prevents or delays the onset of diabetes5. However, achieving a durable weight reduction of 5 to 10 per cent is very difficult in primary care settings for those with more severe or class 2 obesity (BMI higher than 35 kg/m2). Studies using lifestyle and dieting programmes, with or without counselling, have not been able to demonstrate clinically meaningful and sustained weight loss2. The advent of injectable glucagon-like peptide 1 (GLP-1) analogues that work through modulating hunger and satiety can achieve up to 15 per cent weight loss6. However, the treatment is expensive (in the US, 1 month of a weekly injectable GLP-1 analogue costs $1300) and a third do not respond or experience side effects, leading to discontinuation of treatment. Long-term outcomes are variable, with two-thirds of patients regaining weight after stopping GLP-1 analogue treatment. Long-term complications associated with drug therapies also remain of some concern (cardiac valvular fibrosis, stroke, cancer, and suicide). Endoscopic therapies are an option for the treatment of obesity. Intragastric balloons are inserted and removed endoscopically and temporarily (4, 6, or 12 months) occupy space in the stomach, altering gastric volume and motility. Endoscopic sleeve gastroplasty (ESG) requires advanced endoscopic skills; it consists of an endoscope fitted with a suturing device and involves placing full-thickness intragastric sutures to narrow and shorten the stomach. These endoscopic therapies can lead to a 10 to 15 per cent total body weight loss7. However, the duration of weight loss needs further evaluation in long-term studies. Balloons can cause side effects, particularly immediately after insertion and thus are not tolerated by all. Although one balloon can be swallowed as a pill, most balloons and ESGs require hospital admission and the support of anaesthetic teams, adding to the cost. ESG is still relatively expensive, costing upwards of £8000, comparable to the cost of a laparoscopic sleeve gastrectomy. There is a clear need to develop cheaper but effective interventions that can offer 10 to 15 per cent weight loss. Although long-term weight loss is the goal, temporary weight loss may alter the natural history of the disease and have a clinically significant impact. Unquestionably, day case/outpatient therapies would increase patient access to interventions, improve acceptability, and reduce cost. This has led to the development of several innovative bariatric therapies, including endoscopic duodenal mucosal resurfacing, fenestrated gastrostomy tubes, and vagus nerve inhibition. Innovation in the field of weight loss is potentially hugely lucrative given the prevalence of obesity. Innovative interventions have been subject to less rigorous evaluation than medical therapies, and some of these interventions have been approved by regulators without comparative effectiveness studies. This is disappointing and potentially exposes patients to harm and wastes precious healthcare resources. Rigorous evaluation of innovative bariatric interventions is crucially important. These devices should be developed within the IDEAL framework. Over recent years placebo randomized clinical trials (RCTs) in arthroscopy and coronary stenting have been successfully performed with illuminating results8,9. It is now time to expand these studies into bariatric surgery. Some may consider it unethical to expose patients to an invasive placebo procedure, but it may be more unethical to adopt an innovative procedure that subsequently proves to be ineffective or even harmful. This viewpoint is shared by others10, and applies not only to bariatric, but also to other surgical procedures. RCTs in the field of weight loss focus on objective outcomes of weight loss such as weight loss in absolute kilograms, or percentage weight loss or percentage BMI reduction at year 1 post-intervention as their primary outcomes. A core outcome set for bariatric surgery outcomes has been previously proposed11. It may be more useful for future trials to investigate longer-term outcomes (5 and 10 years), including comorbidity resolution and improvement in quality of life. Left gastric artery embolization (LGAE) is an innovation currently in the early phases of evaluation. Embolization of the gastric vessels is established for other conditions, such as gastric haemorrhage. Recently, experimental models showed that LGAE also results in a reduction in gastric emptying and suppression of ghrelin (a hunger hormone) levels, resulting in weight loss. Early developmental case studies (Stage 2a of the IDEAL framework) have refined the technical feasibility and safety. Early data suggest that LGAE can result in 10 per cent weight loss in the intermediate term, and appears to be safe. These intermediate-term results are promising, and the next step is to explore the use of LGAE for the treatment of clinical obesity and whether these selected cases can be replicated in a normal clinical population in normal clinical practice. By evaluating LGAE it should prove possible to better define the mechanism of action (reduction in ghrelin, but other gastrointestinal neuropeptides may be involved) and also gather valuable data on patient response and opinions. This will then help guide larger clinical trials to assess whether this new technique should be offered as a treatment on the NHS. The EMBIO trial received independent funding from the UK National Institute for Health and Care Research and is a multicentre, double-blinded RCT of LGAE versus a placebo procedure. It is designed to evaluate LGAE as a treatment option for obesity and evaluate its safety profile. It will involve 76 participants randomized in a 1:1 ratio to LGAE or placebo procedure (involving radial artery puncture and insertion of a sheath with C arm gantry movements in an equivalent manner to the LGAE procedure without radiation exposure)12. The objectives of this study are to evaluate weight loss and obesity-related comorbidities, to understand mechanisms of action of LGAE, and to assess the safety of LGAE by adverse event recording. A.R.A.’s EMBIO study is funded by National Institute for Health and Care Research. Efficacy and Mechanism Evaluation Programme grant ID: 17/11/49. There is no funding for this publication. The authors declare no conflict of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
No takes yet. Share an insight, caveat, or question.
Ahmed R. Ahmed (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: